

Señores

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

DIVISIÓN DE NUEVAS CREACIONES

E. _____ S. _____

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 07-135475- -00002-0000

Fecha: 2008-03-10 15:52:08 Dep. 2020 NUECREACIONE
Tra. 11 PATENTEIYII Eve: 379 FASENACIONALI
Act. 444 RESPUESTAREQUE Folios: 163

Ref.: Expediente No. 07-135.475

**Solicitud de Patente de Invención titulada: "DERIVADOS DE BENZOFURARONA
COMO MODULADORES NO ESTEROIDES DE RECEPTORES DE
PROGESTERONA"**

Solicitante: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

Nuestra Ref.: P2007/000220

RESPUESTA AL OFICIO No. 834 NOTIFICADO

POR FIJACION EN LISTA No. 18, DE FECHA 25 DE ENERO DE 2008

(EXAMEN DE FORMA)

J. IAN RAISBECK, mayor de edad y vecino de Bogotá, identificado tal como aparece al pie de mi firma, en mi carácter de apoderado de la sociedad en referencia, me permito dar respuesta al auto proferido por ese Despacho, dentro del término legal previsto en el artículo 39 de la Decisión 486, en los siguientes términos:

1. En respuesta a la primera observación del Examinador, me permito adjuntar copia del Reporte de Examen Preliminar Internacional de Patentabilidad, junto con su correspondiente traducción.
2. En respuesta a la segunda observación del Examinador, me permito adjuntar a la solicitud el documento de cesión debidamente legalizado, junto con su correspondiente traducción, según lo previsto en el Art. 26- k de la Decisión 486.

Atentamente,



J. IAN RAISBECK
CC. No. 79.376.996 de Bogotá
T.P. 135.799 CSJ

Anexos: Reporte de Examen Preliminar Internacional de Patentabilidad
Documento de Cesión

TRATADO DE COOPERACIÓN INTERNACIONAL EN MATERIA DE PATENTES

PCT

INFORME DE EXAMEN PRELIMINAR INTERNACIONAL SOBRE PATENTABILIDAD (Capítulo II del Tratado de Cooperación Internacional en Materia de Patentes)

(Artículo PCT 36 y regla PCT 70)

Referencia del Solicitante o Agente 53338AWO	PROCEDER Ver formulario PCT/IPEA/416)	
Referencia Internacional PCT/EP 2006/006532	Fecha de Presentación Internacional (día/mes/año) 22.06.2005	Fecha de Prioridad (día/mes/año) 24.06.2005
Clasificación Internacional de Patente (CIP) o Clasificación Nacional y CIP INV. C07D307/83		
Solicitante SCHERING AKTIENGESELLSCHAFT		

- Este informe se trata del Examen Preliminar Internacional, confeccionado por el organismo encargado del Examen Preliminar Internacional según el artículo 35 y enviado al solicitante según el artículo 36.
- Este INFORME comprende, en total, 5 hojas, incluida esta carátula.
- Además, este informe posee ANEXOS; los mismos comprenden:
 - ☒ (remitidos al solicitante y a la Oficina Internacional) en total 79 hojas; aquí se trata de:
 - ☒ hojas con las descripciones, reivindicaciones, y/o ilustraciones que fueron modificadas y en las cuales se basa este informe y/u hojas con correcciones que aprobó el organismo (ver regla 70.16 y sector 607 de los reglamentos administrativos de PCT).
 - ☐ hojas que reemplazan hojas anteriores pero que, según opinión del organismo, contienen una modificación por los motivos indicados en el campo N° 1, punto 4, superando el contenido revelado en la Solicitud Internacional en la versión presentada originalmente.
 - ☐ (remitidos solo a la Oficina Internacional) en total (rogamos indicar tipo y cantidad del (los) soporte(s) electrónico(s) que contiene(n), solo en forma legible por computadora, el (los) protocolo de secuencias y/o las tablas correspondientes tal como está indicado en el campo suplementario referido al protocolo de secuencias (ver sector 802 de las normas administrativas).

- Este informe contiene indicaciones acerca de los siguientes puntos:
 - ☒ Campo N° I Fundamento del informe
 - ☐ Campo N° II Prioridad
 - ☐ Campo N° III No realización de ningún dictamen sobre novedad, actividad inventiva y aplicabilidad industrial
 - ☐ Campo N° IV Falta de uniformidad de la invención
 - ☒ Campo N° V Resolución fundada según el artículo 35(2) con respecto a la novedad, la actividad inventiva y la aplicabilidad industrial; antecedentes y declaraciones destinados a apoyar esta resolución.
 - ☐ Campo N° VI Documentos específicos expuestos
 - ☐ Campo N° VII Carencias específicas de la solicitud internacional
 - ☐ Campo N° VIII Observaciones específicas a la solicitud internacional

Fecha de presentación de la solicitud 2006.10.14	Fecha de confección de este informe 09.10.2007
nombre y dirección postal del organismo encargado del examen preliminar internacional European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Holanda Tel. (+31-70) 340-2040; Tx: 31 651 epo nl Fax: (+31-70) 340-3016	Funcionario Apoderado Fritz. Martin Tel: +31 70 340-3024

436
✓

Campo N° I	Fundamento del Informe
------------	------------------------

1. Con respecto al **idioma**, el informe está basado sobre
 - ☒ la solicitud internacional en el idioma en que fue presentada
 - ☐ una traducción del idioma original al siguiente idioma, el que se trata del idioma de la traducción suministrada a los siguientes efectos:
 - ☐ búsqueda internacional (según reglas 12.3 y 23.1 b))
 - ☐ publicación de la solicitud internacional (según regla 12.4(a))
 - ☐ examen preliminar internacional (según regla 55.2 y 55.3)
2. Con respecto a los **elementos*** de la Solicitud Internacional, el informe se basa en *(las hojas de reemplazo que fueron presentadas al organismo como invitación según el artículo 14 son válidas como "presentadas originalmente" en el marco de este informe y no se adjuntan):*

Descripción, páginas

1-72 en la versión presentada originalmente

Reivindicaciones, N°

1 – 25 recibidas el 04.10.2006 con escrito del 29.09.2006

- ☐ un listado de secuencias y/o eventual(es) tabla(s) relacionada(s) – con respecto al protocolo de secuencias, ver campo adicional.
3. ☐ Como consecuencia de las modificaciones caducaron los siguientes documentos:
 - ☐ Descripción: páginas
 - ☐ Reivindicaciones N°: 29, 30
 - ☐ Ilustraciones: hoja/figura
 - ☐ Listado de secuencias (*especificar*):
 - ☐ Eventual(es) tabla(s) perteneciente(s) al listado de secuencias (*especificar*):
 4. ☐ Este informe fue elaborado sin tomar en consideración (algunas de) las modificaciones adjuntas a este informe, dado que se considera que las mismas exceden el contenido revelado en el texto presentado originalmente (regla 70.2(c)), tal como se indica en el campo suplementario.
 - ☐ Descripción: páginas
 - ☐ Reivindicaciones N°:
 - ☐ Ilustraciones: hojas/figuras
 - ☐ Listado de secuencias (*especificar*):
 - ☐ Eventual(es) tabla(s) perteneciente(s) al listado de secuencias (*especificar*):

* Cuando corresponde el punto 4, algunas o todas estas hojas pueden estar provistas de la observación "reemplazada".

**INFORME PRELIMINAR INTERNACIONAL
SOBRE PATENTABILIDAD**

Referencia Internacional
PCT/EP 2006/006532

437
5

Campo N° V	Resolución fundada según el artículo 35(2) con respecto a la novedad, la actividad inventiva y la aplicabilidad industrial; documentos y declaraciones destinadas a apoyar esta resolución
------------	--

1. Resolución

Novedad (N)	Sí	Reivindicaciones:	<u>1-25</u>
	No	Reivindicaciones:	
Actividad inventiva (IS)	Sí	Reivindicaciones:	<u>13</u>
	No	Reivindicaciones:	<u>1-12, 14-25</u>
Aplicabilidad industrial (IA)	Sí	Reivindicaciones:	<u>1-25</u>
	No	Reivindicaciones:	

2. Antecedentes y declaraciones (regla 70.7):

ver hoja adjunta

4381
6

**V Resolución fundada según la regla 66.2(a)(ii) con respecto a la
novedad, la actividad inventiva y la aplicabilidad industrial;
antecedentes y declaraciones destinados a apoyar esta resolución**

D1: WO 03/075915 A (SCHERING AG; SCHMEES, NORBERT; LEHMANN,
MANFRED; FUHRMANN, ULRIKE; MUH) 18 de septiembre de 2003
(2003.09.18)

La presente solicitud se refiere a compuestos que responden a la fórmula
general I (reivindicaciones 1-13), composiciones farmacéuticas de los mismos
(reivindicaciones 14-16) y el uso de los mismos en la preparación de un agente
farmacéutico (reivindicaciones 17-25).

Los compuestos I pueden distinguirse de los compuestos más preferidos
acordes con D1 (ver fórmula estructural (1) en la página 10) por la definición de
 R^3 , que se trata de un alquinilo sustituido por R^a o un alquenilo sustituido por
 R^g , R^h (el sustituyente análogo en el compuesto (1)) de D1 es un grupo
trifluorometilo).

El objeto de las reivindicaciones 1-25 acordes con el presente caso es, por ello,
novedoso en el sentido del artículo PCT 33(2).

El estado de la técnica más cercano es D1.

El problema que plantea la presente solicitud es proveer otros compuestos que
actúen como moduladores de receptores de progesterona no esteroides y,
como tales, útiles en el tratamiento de ciertos trastornos ginecológicos.

Este problema ha sido resuelto por aquellos compuestos (I) en los cuales

A representa un grupo cíclico,
 R^3 representa un alquinilo opcionalmente sustituido,

como se puede apreciar en la descripción.

Para lograr esto, partiendo del compuesto (1) de D1 como representante de los
compuestos (I) del presente caso, un experto debe reemplazar el grupo
trifluorometilo localizado en la posición α del grupo amido de este compuesto
conocido por un grupo alquinilo o alquenilo opcionalmente sustituido. De
acuerdo con la definición más amplia de los compuestos dados a conocer en
D1 (constituidos por la reivindicación 1 de este documento), el carbono
localizado en posición α del grupo amido debe ser sustituido por un
trifluorometilo o, alternativamente, un grupo metilo.

**INFORME PRELIMINAR INTERNACIONAL
SOBRE PATENTABILIDAD
(HOJA ADJUNTA)**

Referencia Internacional
PCT/EP 2006/006532

439

X

El experto que tiene conocimiento de D1 no posee entonces incentivos para reemplazar este sustituyente por un grupo químico diferente, tal como un alquinilo/alquenilo opcionalmente sustituido.

En consecuencia, los compuestos (I) acordes con el presente caso no son obvios a la luz de los compuestos dados a conocer en D1.

No está claro, debido a las definiciones (aparentemente muy amplias) de A y R³ (*vide supra*), si todos los compuestos reivindicados constituyen una solución al problema; por ello, sólo se reconoce actividad inventiva en el sentido del artículo PCT 33(3) para el objeto de la reivindicación 13.

Otras objeciones:

Contrariamente a los requisitos de la regla PCT 5.1(a)(ii), en la descripción no se menciona el estado fundamental relevante revelado en el documento D1 ni está identificado este documento en ella.

Tal como se presentaron las reivindicaciones enmendadas, la descripción puede ser llevada a conformidad con las mismas (artículo PCT 6). Esto puede ser realizado en una eventual fase nacional.


REIVINDICACIONES CON ENMIENDAS

Recibidas en la OFICINA internacional el 4 de octubre de 2006 (4/10/2006)

Declaración

Reivindicaciones

1. Compuestos de la fórmula general I



en donde

R^1 y R^2 son, de modo independiente entre sí, un átomo de hidrógeno, un grupo alquilo C_1-C_5 lineal o no lineal, ramificado o no ramificado, que además forma junto con el átomo de C de la cadena un anillo con un total de 3–7 miembros,

R^3 es un radical $C\equiv C-R^a$, en donde

R^a es un átomo de hidrógeno o un alquilo C_1-C_8 , alqueno C_2-C_8 , alquino C_2-C_8 , cicloalquilo C_3-C_{10} , heterocicloalquilo eventualmente mono- o polisustituido, igual o diferente, con K o un arilo o heteroarilo eventualmente mono- o polisustituido, igual o diferente, con L,

K es ciano, halógeno, hidroxilo, nitro, $-C(O)R^b$, CO_2R^b , $-O-R^b$, $-S-R^b$, $SO_2NR^cR^d$, $-C(O)-NR^cR^d$, $-OC(O)-NR^cR^d$, $-C=NOR^b$, $-NR^cR^d$ o un cicloalquilo C_3-C_{10} , heterocicloalquilo eventualmente mono- o polisustituido, igual o diferente, con M o arilo o heteroarilo eventualmente mono- o polisustituido con L,

L es alquilo C_1-C_8 , alqueno C_2-C_8 , alquino C_2-C_8 , perfluoroalquilo C_1-C_6 , perfluoroalcoxi C_1-C_6 , alcoxi C_1-C_6 -alcoxi C_1-C_6 , $(CH_2)_p-$

cicloalquilo C_3-C_{10} , $(CH_2)_p$ -heterocicloalquilo, $(CH_2)_pCN$, $(CH_2)_pHal$,

$(CH_2)_pNO_2$, $(CH_2)_p$ -arilo C_6-C_{12} , $(CH_2)_p$ -heteroarilo,

$-(CH_2)_pPO_3(R^b)_2$,

$-(CH_2)_pNR^cR^d$, $-(CH_2)_pNR^cCOR^b$,

$-(CH_2)_pNR^cCSR^b$, $-(CH_2)_pNR^cS(O)R^b$,

$-(CH_2)_pNR^cS(O)_2R^b$,

$-(CH_2)_pNR^cCONR^cR^d$,

$-(CH_2)_pNR^cCOOR^b$,

$-(CH_2)_pNR^cC(NH)NR^cR^d$,

$-(CH_2)_pNR^cCSNR^cR^d$,

$-(CH_2)_pNR^cS(O)NR^cR^d$,

$-(CH_2)_pNR^cS(O)_2NR^cR^d$, $-(CH_2)_pCOR^b$,

$-(CH_2)_pCSR^b$, $-(CH_2)_pS(O)R^b$,

$-(CH_2)_pS(O)(NH)R^b$, $-(CH_2)_pS(O)_2R^b$,

$-(CH_2)_pS(O)_2NR^cR^d$, $-(CH_2)_pSO_2OR^b$,

$-(CH_2)_pCO_2R^b$, $-(CH_2)_pCONR^cR^d$,

$-(CH_2)_pCSNR^cR^d$, $-(CH_2)_pOR^b$,

$-(CH_2)_pSR^b$, $-(CH_2)_pCR^b(OH)-R^e$,

$-(CH_2)_p-C=NOR^b$, $-O-(CH_2)_n-O-$,

$-O-(CH_2)_n-CH_2-$, $-O-CH=CH-$ o

$-(CH_2)_{n+2}-$, en donde es $n = 1$ ó 2 y los átomos de oxígeno y/o átomos de carbono terminales están unidos con átomos de carbono del anillo directamente adyacentes,

M es alquilo C_1-C_6 o un grupo

$-COR^b$, CO_2R^b , $-O-R^b$ o $-NR^cR^d$, en donde

R^b es un átomo de hidrógeno o un alquilo C_1-C_6 , alqueno C_2-C_8 , alquino C_2-C_8 , cicloalquilo C_3-C_{10} , arilo C_6-C_{12} o perfluoroalquilo C_1-C_3 y

R^c y R^d son, de modo independiente entre sí, un átomo de hidrógeno, alquilo C_1-C_6 , alqueno C_2-C_8 , alquino C_2-C_8 , cicloalquilo C_3-C_{10} , arilo C_6-C_{12} , $C(O)R^b$ o un grupo hidroxilo, en donde cuando

R^c es un grupo hidroxilo, R^d sólo puede ser un átomo de hidrógeno, un alquilo C_1-C_6 , alqueno C_2-C_8 , alquino C_2-C_8 , cicloalquilo C_3-C_{10} o arilo C_6-C_{12} y viceversa, así como

R^e es un átomo de hidrógeno, alquilo C_1-C_6 , alqueno C_2-C_8 , alquino C_2-C_8 , cicloalquilo C_3-C_{10} o arilo C_6-C_{12} y

p puede ser una cifra de 0 a 6,

o

R^3 es un radical $C=C-R^gR^h$, en donde

R^g y R^h son, de modo independiente entre sí, un átomo de hidrógeno o un alquilo C_1-C_8 , alqueno C_2-C_8 o alquino C_2-C_8 eventualmente mono- o polisustituido, igual o diferente, con X, en donde

X es un ciano, halógeno, hidroxilo, nitro, $-C(O)R^b$, CO_2R^b , $-O-R^b$, $-C(O)-NR^cR^d$, $-NR^cR^d$ con los significados ya mencionados más arriba para R^b , R^c y R^d y

R^{4a} y R^{4b} son, de modo independiente entre sí, un átomo de hidrógeno, un alquilo C_1-C_4 , un alqueno C_2-C_4 o forman, junto con el átomo de carbono del anillo, un anillo de 3-6 miembros,

A es un anillo aromático carbocíclico o heterocíclico mono- o bicíclico, que puede estar eventualmente mono- o polisustituido con alquilo C₁-C₈, alquenilo C₂-C₈, alquinilo C₂-C₈, perfluoroalquilo C₁-C₆, perfluoroalcoxi C₁-C₆, alcoxi C₁-C₆-alquilo C₁-C₆, alcoxi C₁-C₆-alcoxi C₁-C₆, (CH₂)_p-cicloalquilo C₃-C₁₀, (CH₂)_p-heterocicloalquilo, (CH₂)_pCN, (CH₂)_pHal, (CH₂)_pNO₂, (CH₂)_p-arilo C₆-C₁₂, (CH₂)_p-heteroarilo, -(CH₂)_pPO₃(R^b)₂, -(CH₂)_pNR^cR^d, -(CH₂)_pNR^eCOR^b, -(CH₂)_pNR^eCSR^b, -(CH₂)_pNR^eS(O)R^b, -(CH₂)_pNR^eS(O)₂R^b, -(CH₂)_pNR^eCONR^cR^d, -(CH₂)_pNR^eCOOR^b, -(CH₂)_pNR^eC(NH)NR^cR^d, -(CH₂)_pNR^eCSNR^cR^d, -(CH₂)_pNR^eS(O)NR^cR^d, -(CH₂)_pNR^eS(O)₂NR^cR^d, -(CH₂)_pCOR^b, -(CH₂)_pCSR^b, -(CH₂)_pS(O)R^b, -(CH₂)_pS(O)(NH)R^b, -(CH₂)_pS(O)₂R^b, -(CH₂)_pS(O)₂NR^cR^d, -(CH₂)_pSO₂OR^b, -(CH₂)_pCO₂R^b, -(CH₂)_pCONR^cR^d, -(CH₂)_pCSNR^cR^d, -(CH₂)_pOR^b, -(CH₂)_pSR^b, -(CH₂)_pCR^b(OH)-R^d, -(CH₂)_p-C=NOR^b, -O-(CH₂)_n-O-, -O-(CH₂)_n-CH₂-, -O-CH=CH- o -(CH₂)_{n+2}-, en donde es n = 1 ó 2 y los átomos de oxígeno y/o átomos de carbono están unidos con átomos de carbono del anillo directamente adyacentes o

A es un radical -CO₂R^b, C(O)NR^cR^d, COR^b,

o

A es un grupo alquenilo -CR⁵=CR⁶R⁷, en donde

R⁵, R⁶ y R⁷ son iguales o diferentes y, de modo independiente entre sí, son átomos de hidrógeno, átomos de halógeno, radicales arilo o un grupo alquilo C₁-C₅ no sustituido o parcial o totalmente fluorado o

A es un grupo alquinilo $-C\equiv CR^5$, con el significado indicado arriba para R^5 y

B es un grupo carbonilo o un grupo CH_2 ,

así como sus sales farmacéuticamente aceptables.

2. Compuestos de acuerdo con la reivindicación 1, en donde R^1 y R^2 son preferentemente un átomo de hidrógeno, un grupo metilo o etilo.

3. Compuestos de acuerdo con la reivindicación 1, en donde R^1 y R^2 forman con preferencia, junto con el átomo de C de la cadena, un anillo con un total de 3–7 miembros.

4. Compuestos de acuerdo con la reivindicación 1 a 3, en donde R^3 es preferentemente alquenilo, alquinilo, arilalquinilo, heteroarilalquinilo, cicloalquilalquinilo, heterocicloalquilalquinilo.

5. Compuestos de acuerdo con una de las reivindicaciones precedentes, en donde R^3 es preferentemente un grupo vinilo, etinilo, propinilo, butinilo, pentinilo, hexinilo, heptinilo, octinilo, hidroxipropinilo, hidroxibutinilo, 3–hidroxi–3–metilbutinilo, hidroxipentinilo, carboxipropinilo, t–butilcarboxipropinilo, feniletinilo, (hidroxifenil)etinilo, (metoxifenil)etinilo, (dimetilaminofenil)etinilo, (metilfenil)etinilo, (cianofenil)etinilo, (trifluorometil)etinilo, (difenil)etinilo, (nitrofenil)etinilo, (ter–butilfenil)etinilo, (acetilfenil)etinilo, (acetoxifenil)etinilo, (carboxifenil)etinilo o benciletinilo.

6. Compuestos de acuerdo con una de las reivindicaciones precedentes, en donde A es preferentemente un anillo aromático.

7. Compuestos de acuerdo con una de las reivindicaciones precedentes, en donde A es preferentemente un radical fenilo o naftilo.

8. Compuestos de acuerdo con la reivindicación 7, en donde A es preferentemente un radical fenilo no sustituido o eventualmente mono– o polisustituido.





9. Compuestos de acuerdo con la reivindicación 8, en donde el radical fenilo está sustituido preferentemente con uno o dos átomos de halógeno o un grupo trifluorometilo.


10. Compuestos de acuerdo con la reivindicación 9, en donde los átomos de halógeno son preferentemente cloro y/o flúor.











11. Compuestos de acuerdo con las reivindicaciones 1-8, en donde A es preferentemente un anillo fenilo sustituido con $-O-(CH_2)_n-O-$ u $-O-(CH_2)_n-CH_2-$, en donde los átomos de carbono del anillo directamente adyacentes están unidos.






12. Compuestos de acuerdo con una de las reivindicaciones precedentes, en donde R^{4a} y R^{4b} son en cada caso, de modo independiente entre sí, un átomo de hidrógeno.



13. Compuestos de acuerdo con la reivindicación 1 a 12, a saber


N.º	Racémico enantiómero	o R3
1	rac	
2	+	
3	-	
4	rac	
5	+	
6	-	
7	rac	
8	+	
9	-	
10	rac	
11	+	
12	-	
13	rac	













14	+	
15	-	
16	rac	
17	+	
18	-	
19	rac	
20	+	
21	-	
22	rac	
23	+	
24	-	
25	rac	
26	+	
27	-	
28	rac	
29	+	
30	-	
31	rac	
32	+	
33	-	
34	rac	
35	+	
36	-	
37	rac	
38	+	
39	-	
40	rac	
41	+	
42	-	
43	rac	
44	+	

45	—	
46	rac	
47	+	
48	—	
49	rac	
50	+	
51	—	
52	rac	
53	+	
54	—	
55	rac	
56	+	
57	—	
58	rac	
59	+	
60	—	


N.º	Racémico enantiómero	o R3
61	rac	
62	+	
63	—	
64	rac	
65	+	
66	—	
67	rac	
68	+	
69	—	
70	rac	
71	+	



72	—	
73	rac	
74	+	
75	—	
76	rac	
77	+	
78	—	
79	rac	
80	+	
81	—	
82	rac	
83	+	
84	—	
85	rac	
86	+	
87	—	
88	rac	
89	+	
90	—	
91	rac	
92	+	
93	—	
94	rac	
95	+	
96	—	
97	rac	
98	+	
99	—	
100	rac	
101	+	
102	—	











103	rac	
104	+	
105	—	
106	rac	
107	+	
108	—	
109	rac	
110	+	
111	—	
112	rac	
113	+	
114	—	
115	rac	
116	+	
117	—	
118	rac	
119	+	
120	—	

N.º	Racémico enantiómero	o R3
121	rac	
122	+	
123	—	
124	rac	
125	+	
126	—	
127	rac	
128	+	
129	—	









450


18


130	rac	
131	+	
132	-	
133	rac	
134	+	
135	-	
136	rac	
137	+	
138	-	
139	rac	
140	+	
141	-	
142	rac	
143	+	
144	-	
145	rac	
146	+	
147	-	
148	rac	
149	+	
150	-	
151	rac	
152	+	
153	-	
154	rac	
155	+	
156	-	
157	rac	
158	+	
159	-	
160	rac	











451

79

161	+	
162	-	
163	rac	
164	+	
165	-	
166	rac	
167	+	
168	-	
169	rac	
170	+	
171	-	
172	rac	
173	+	
174	-	
175	rac	
176	+	
177	-	
178	rac	
179	+	
180	-	








N.º	Racémico enantiómero	o R3
181	rac	
182	+	
183	-	
184	rac	
185	+	
186	-	
187	rac	





188	+	
189	-	
190	rac	
191	+	
192	-	
193	rac	
194	+	
195	-	
196	rac	
197	+	
198	-	
199	rac	
200	+	
201	-	
202	rac	
203	+	
204	-	
205	rac	
206	+	
207	-	
208	rac	
209	+	
210	-	
211	rac	
212	+	
213	-	
214	rac	
215	+	
216	-	
217	rac	
218	+	









453

21

219	—	
220	rac	
221	+	
222	—	
223	rac	
224	+	
225	—	
226	rac	
227	+	
228	—	
229	rac	
230	+	
231	—	
232	rac	
233	+	
234	—	
235	rac	
236	+	
237	—	
238	rac	
239	+	
240	—	









N.º	Racémico enantiómero	o R3
241	rac	
242	+	
243	—	
244	rac	
245	+	





246	—	
247	rac	
248	+	
249	—	
250	rac	
251	+	
252	—	
253	rac	
254	+	
255	—	
256	rac	
257	+	
258	—	
259	rac	
260	+	
261	—	
262	rac	
263	+	
264	—	
265	rac	
266	+	
267	—	
268	rac	
269	+	
270	—	
271	rac	
272	+	
273	—	
274	rac	
275	+	
276	—	












455

23










277	rac	
278	+	
279	-	
280	rac	
281	+	
282	-	
283	rac	
284	+	
285	-	
286	rac	
287	+	
288	-	
289	rac	
290	+	
291	-	
292	rac	
293	+	
294	-	
295	rac	
296	+	
297	-	
298	rac	
299	+	
300	-	


N.º	Racémico enantiómero	o R3
301	rac	
302	+	
303	-	












304	rac	
305	+	
306	-	
307	rac	
308	+	
309	-	
310	rac	
311	+	
312	-	
313	rac	
314	+	
315	-	
316	rac	
317	+	
318	-	
319	rac	
320	+	
321	-	
322	rac	
323	+	
324	-	
325	rac	
326	+	
327	-	
328	rac	
329	+	
330	-	
331	rac	
332	+	
333	-	
334	rac	










25

335	+	
336	-	
337	rac	
338	+	
339	-	
340	rac	
341	+	
342	-	
343	rac	
344	+	
345	-	
346	rac	
347	+	
348	-	
349	rac	
350	+	
351	-	
352	rac	
353	+	
354	-	
355	rac	
356	+	
357	-	
358	rac	
359	+	
360	-	


N.º	Racémico enantiómero	o R3
361	rac	



362	+	
363	—	
364	rac	
365	+	
366	—	
367	rac	
368	+	
369	—	
370	rac	
371	+	
372	—	
373	rac	
374	+	
375	—	
376	rac	
377	+	
378	—	
379	rac	
380	+	
381	—	
382	rac	
383	+	
384	—	
385	rac	
386	+	
387	—	
388	rac	
389	+	
390	—	
391	rac	
392	+	









393	—	
394	rac	
395	+	
396	—	
397	rac	
398	+	
399	—	
400	rac	
401	+	
402	—	
403	rac	
404	+	
405	—	
406	rac	
407	+	
408	—	
409	rac	
410	+	
411	—	
412	rac	
413	+	
414	—	
415	rac	
416	+	
417	—	
418	rac	
419	+	
420	—	

N.º	Racémico	o R3
-----	----------	------













460


28









	enantiómero	
421	rac	
422	+	
423	-	
424	rac	
425	+	
426	-	
427	rac	
428	+	
429	-	
430	rac	
431	+	
432	-	
433	rac	
434	+	
435	-	
436	rac	
437	+	
438	-	
439	rac	
440	+	
441	-	
442	rac	
443	+	
444	-	
445	rac	
446	+	
447	-	
448	rac	
449	+	
450	-	

461

201











451	rac	
452	+	
453	-	
454	rac	
455	+	
456	-	
457	rac	
458	+	
459	-	
460	rac	
461	+	
462	-	
463	rac	
464	+	
465	-	
466	rac	
467	+	
468	-	
469	rac	
470	+	
471	-	
472	rac	
473	+	
474	-	
475	rac	
476	+	
477	-	
478	rac	
479	+	
480	-	
N. °	Racémico	o R3



	enantiómero	
481	rac	
482	+	
483	-	
484	rac	
485	+	
486	-	
487	rac	
488	+	
489	-	
490	rac	
491	+	
492	-	
493	rac	
494	+	
495	-	
496	rac	
497	+	
498	-	
499	rac	
500	+	
501	-	
502	rac	
503	+	
504	-	
505	rac	
506	+	
507	-	
508	rac	
509	+	
510	-	









463


m

511	rac	
512	+	
513	-	
214	rac	
515	+	
516	-	
517	rac	
518	+	
519	-	
520	rac	
521	+	
522	-	
523	rac	
524	+	
525	-	
526	rac	
227	+	
528	-	
529	rac	
530	+	
531	-	
532	rac	
533	+	
534	-	
535	rac	
536	+	
537	-	
538	rac	
539	+	
540	-	

464












32

N.º	Racémico enantiómero	o R3
541	rac	
542	+	
543	—	
544	rac	
545	+	
546	—	
547	rac	
548	+	
549	—	
550	rac	
551	+	
552	—	
553	rac	
554	+	
555	—	
556	rac	
557	+	
558	—	
559	rac	
560	+	
561	—	
562	rac	
563	+	
564	—	
565	rac	
566	+	
567	—	



465









33


568	rac	
569	+	
570	-	
571	rac	
572	+	
573	-	
574	rac	
575	+	
576	-	
577	rac	
578	+	
579	-	
580	rac	
581	+	
582	-	
583	rac	
584	+	
585	-	
586	rac	
587	+	
588	-	
589	rac	
590	+	
591	-	
592	rac	
593	+	
594	-	
595	rac	
596	+	
597	-	
598	rac	

466











34

599	+	
600	-	

N.º	Racémico enantiómero	o R3
601	rac	
602	+	
603	-	
604	rac	
605	+	
606	-	
607	rac	
608	+	
609	-	
610	rac	
611	+	
612	-	
613	rac	
614	+	
615	-	
616	rac	
617	+	
618	-	
619	rac	
620	+	
621	-	
622	rac	
623	+	
624	-	
625	rac	











25











626	+	
627	-	
628	rac	
629	+	
630	-	
631	rac	
632	+	
633	-	
634	rac	
635	+	
636	-	
637	rac	
638	+	
639	-	
640	rac	
641	+	
642	-	
643	rac	
644	+	
645	-	
646	rac	
647	+	
648	-	
649	rac	
650	+	
651	-	
652	rac	
653	+	
654	-	
655	rac	
656	+	

468

36

657	—	
658	rac	
659	+	
660	—	

N.º	Racémico enantiómero	o R3
661	rac	
662	+	
663	—	
664	rac	
665	+	
666	—	
667	rac	
668	+	
669	—	
670	rac	
671	+	
672	—	
673	rac	
674	+	
675	—	
676	rac	
677	+	
678	—	
679	rac	
680	+	
681	—	
682	rac	
683	+	


684	—	
685	rac	
686	+	
687	—	
688	rac	
689	+	
690	—	
691	rac	
692	+	
693	—	
694	rac	
695	+	
696	—	
697	rac	
698	+	
699	—	
700	rac	
701	+	
702	—	
703	rac	
704	+	
705	—	
706	rac	
707	+	
708	—	
709	rac	
710	+	
711	—	
712	rac	
713	+	
714	—	












470



38







715	rac	
716	+	
717	-	
718	rac	
719	+	
720	-	

N.º	Racémico enantiómero	R3
721	rac	
722	+	
723	-	
724	rac	
725	+	
726	-	
727	rac	
728	+	
729	-	
730	rac	
731	+	
732	-	
733	rac	
734	+	
735	-	
736	rac	
737	+	
738	-	
739	rac	
740	+	
741	-	












742	rac	
743	+	
744	-	
745	rac	
746	+	
747	-	
748	rac	
749	+	
750	-	
751	rac	
752	+	
753	-	
754	rac	
755	+	
756	-	
757	rac	
758	+	
759	-	
760	rac	
761	+	
762	-	
763	rac	
764	+	
765	-	
766	rac	
767	+	
768	-	
769	rac	
770	+	
771	-	
772	rac	

773	+	 
774	-	
775	rac	
776	+	
777	-	
778	rac	
779	+	
780	-	




N.º	Racémico enantiómero	o R3
781	rac	
782	+	
783	-	
784	rac	
785	+	
786	-	
787	rac	
788	+	
789	-	
790	rac	
791	+	
792	-	
793	rac	
794	+	
795	-	
796	rac	
797	+	
798	-	
799	rac	







41


800	+	
801	—	
802	rac	
803	+	
804	—	
805	rac	
806	+	
807	—	
808	rac	
809	+	
810	—	
811	rac	
812	+	
813	—	
814	rac	
815	+	
816	—	
817	rac	
818	+	
819	—	
820	rac	
821	+	
822	—	
823	rac	
824	+	
825	—	
826	rac	
827	+	
828	—	
829	rac	
830	+	











474





1/2






831	—	
832	rac	
833	+	
834	—	
835	rac	
836	+	
837	—	
838	rac	
839	+	
840	—	


N.º	Racémico enantiómero	o R3
841	rac	
842	+	
843	—	
844	rac	
845	+	
846	—	
847	rac	
848	+	
849	—	
850	rac	
851	+	
852	—	
853	rac	
854	+	
855	—	
856	rac	
857	+	














858	—	
859	rac	
860	+	
861	—	
862	rac	
863	+	
864	—	
865	rac	
866	+	
867	—	
868	rac	
869	+	
870	—	
871	rac	
872	+	
873	—	
874	rac	
875	+	
876	—	
877	rac	
878	+	
879	—	
880	rac	
881	+	
882	—	
883	rac	
884	+	
885	—	
886	rac	
887	+	
888	—	





889	rac	
890	+	
891	-	
892	rac	
893	+	
894	-	
895	rac	
896	+	
897	-	
898	rac	
899	+	
900	-	





N.º	Racémico enantiómero	o R3
901	rac	
902	+	
903	-	
904	rac	
905	+	
906	-	
907	rac	
908	+	
909	-	
910	rac	
911	+	
912	-	
913	rac	
914	+	
915	-	




45











916	rac	
917	+	
918	—	
919	rac	
920	+	
921	—	
922	rac	
923	+	
924	—	
925	rac	
926	+	
927	—	
928	rac	
929	+	
930	—	
931	rac	
932	+	
933	—	
934	rac	
935	+	
936	—	
937	rac	
938	+	
939	—	
940	rac	
941	+	
942	—	
943	rac	
944	+	
945	—	
946	rac	

947	+	
948	-	
949	rac	
950	+	
951	-	
952	rac	
953	+	
954	-	
955	rac	
956	+	
957	-	
958	rac	
959	+	
960	-	






N.º	Racémico enantiómero	o R3
961	rac	
962	+	
963	-	
964	rac	
965	+	
966	-	
967	rac	
968	+	
969	-	
970	rac	
971	+	
972	-	
973	rac	






479

974	+	
975	-	
976	rac	
977	+	
978	-	
979	rac	
980	+	
981	-	
982	rac	
983	+	
984	-	
985	rac	
986	+	
987	-	
988	rac	
989	+	
990	-	
991	rac	
992	+	
993	-	
994	rac	
995	+	
996	-	
997	rac	
998	+	
999	-	
1000	rac	
1001	+	
1002	-	
1003	rac	
1004	+	

48










1005	—	
1006	rac	
1007	+	
1008	—	
1009	rac	
1010	+	
1011	—	
1012	rac	
1013	+	
1014	—	
1015	rac	
1016	+	
1017	—	
1018	rac	
1019	+	
1020	—	

N.º	Racémico enantiómero	o R3
1021	rac	
1022	+	
1023	—	
1024	rac	
1025	+	
1026	—	
1027	rac	
1028	+	
1029	—	
1030	rac	
1031	+	












481

49

1032	—	
1033	rac	
1034	+	
1035	—	
1036	rac	
1037	+	
1038	—	
1039	rac	
1040	+	
1041	—	
1042	rac	
1043	+	
1044	—	
1045	rac	
1046	+	
1047	—	
1048	rac	
1049	+	
1050	—	
1051	rac	
1052	+	
1053	—	
1054	rac	
1055	+	
1056	—	
1057	rac	
1058	+	
1059	—	
1060	rac	
1061	+	
1062	—	












50

1063	rac	
1064	+	
1065	—	
1066	rac	
1067	+	
1068	—	
1069	rac	
1070	+	
1071	—	
1072	rac	
1073	+	
1074	—	
1075	rac	
1076	+	
1077	—	
1078	rac	
1079	+	
1080	—	

N.º	Racémico enantiómero	o R3
1081	rac	
1082	+	
1083	—	
1084	rac	
1085	+	
1086	—	
1087	rac	
1088	+	
1089	—	








483



51


1090	rac	
1091	+	
1092	-	
1093	rac	
1094	+	
1095	-	
1096	rac	
1097	+	
1098	-	
1099	rac	
1100	+	
1101	-	
1102	rac	
1103	+	
1104	-	
1105	rac	
1106	+	
1107	-	
1108	rac	
1109	+	
1110	-	
1111	rac	
1112	+	
1113	-	
1114	rac	
1115	+	
1116	-	
1117	rac	
1118	+	
1119	-	
1120	rac	

484

52








1121	+	
1122	-	
1123	rac	
1124	+	
1125	-	
1126	rac	
1127	+	
1128	-	
1129	rac	
1130	+	
1131	-	
1132	rac	
1133	+	
1134	-	
1135	rac	
1136	+	
1137	-	
1138	rac	
1139	+	
1140	-	



N.º	Racémico enantiómero	o R3
1141	rac	
1142	+	
1143	-	
1144	rac	
1145	+	
1146	-	
1147	rac	




53










1148	+	
1149	—	
1150	rac	
1151	+	
1152	—	
1153	rac	
1154	+	
1155	—	
1156	rac	
1157	+	
1158	—	
1159	rac	
1160	+	
1161	—	
1162	rac	
1163	+	
1164	—	
1165	rac	
1166	+	
1167	—	
1168	rac	
1169	+	
1170	—	
1171	rac	
1172	+	
1173	—	
1174	rac	
1175	+	
1176	—	
1177	rac	
1178	+	

1179	—	
1180	rac	
1181	+	
1182	—	
1183	rac	
1184	+	
1185	—	
1186	rac	
1187	+	
1188	—	
1189	rac	
1190	+	
1191	—	
1192	rac	
1193	+	
1194	—	
1195	rac	
1196	+	
1197	—	
1198	rac	
1199	+	
1200	—	











N.º	Racémico enantiómero	o R3
1201	rac	
1202	+	
1203	—	
1204	rac	
1205	+	




55

1206	—	
1207	rac	
1208	+	
1209	—	
1210	rac	
1211	+	
1212	—	
1213	rac	
1214	+	
1215	—	
1216	rac	
1217	+	
1218	—	
1219	rac	
1220	+	
1221	—	
1222	rac	
1223	+	
1224	—	
1225	rac	
1226	+	
1227	—	
1228	rac	
1229	+	
1230	—	
1231	rac	
1232	+	
1233	—	
1234	rac	
1235	+	
1236	—	









156

1237	rac	
1238	+	
1239	—	
1240	rac	
1241	+	
1242	—	
1243	rac	
1244	+	
1245	—	
1246	rac	
1247	+	
1248	—	
1249	rac	
1250	+	
1251	—	
1252	rac	
1253	+	
1254	—	
1255	rac	
1256	+	
1257	—	
1258	rac	
1259	+	
1260	—	
N. °	Racémico enantiómero	o R3
1261	rac	
1262	+	
1263	—	
1264	rac	
1265	+	












489


57









1266	—	
1267	rac	
1268	+	
1269	—	
1270	rac	
1271	+	
1272	—	
1273	rac	
1274	+	
1275	—	
1276	rac	
1277	+	
1278	—	
1279	rac	
1280	+	
1281	—	
1282	rac	
1283	+	
1284	—	
1285	rac	
1286	+	
1287	—	
1288	rac	
1289	+	
1290	—	
1291	rac	
1292	+	
1293	—	
1294	rac	
1295	+	
1296	—	

50

1297	rac	
1298	+	
1299	-	
1300	rac	
1301	+	
1302	-	
1303	rac	
1304	+	
1305	-	
1306	rac	
1307	+	
1308	-	
1309	rac	
1310	+	
1311	-	
1312	rac	
1313	+	
1314	-	
1315	rac	
1316	+	
1317	-	
1318	rac	
1319	+	
1320	-	








N.º	Racémico enantiómero	o R3
1321	rac	
1322	+	
1323	-	





1324	rac	
1325	+	
1326	-	
1327	rac	
1328	+	
1329	-	
1330	rac	
1331	+	
1332	-	
1333	rac	
1334	+	
1335	-	
1336	rac	
1337	+	
1338	-	
1339	rac	
1340	+	
1341	-	
1342	rac	
1343	+	
1344	-	
1345	rac	
1346	+	
1347	-	
1348	rac	
1349	+	
1350	-	
1351	rac	
1352	+	
1353	-	
1354	rac	










492










60

1355	+	
1356	-	
1357	rac	
1358	+	
1359	-	
1360	rac	
1361	+	
1362	-	
1363	rac	
1364	+	
1365	-	
1366	rac	
1367	+	
1368	-	
1369	rac	
1370	+	
1371	-	
1372	rac	
1373	+	
1374	-	
1375	rac	
1376	+	
1377	-	
1378	rac	
1379	+	
1380	-	


N.º	Racémico enantiómero	o R3
1381	rac	



1382	+	
1383	—	
1384	rac	
1385	+	
1386	—	
1387	rac	
1388	+	
1389	—	
1390	rac	
1391	+	
1392	—	
1393	rac	
1394	+	
1395	—	
1396	rac	
1397	+	
1398	—	
1399	rac	
1400	+	
1401	—	
1402	rac	
1403	+	
1404	—	
1405	rac	
1406	+	
1407	—	
1408	rac	
1409	+	
1410	—	
1411	rac	
1412	+	








1413	—	
1414	rac	
1415	+	
1416	—	
1417	rac	
1418	+	
1419	—	
1420	rac	
1421	+	
1422	—	
1423	rac	
1424	+	
1425	—	
1426	rac	
1427	+	
1428	—	
1429	rac	
1430	+	
1431	—	
1432	rac	
1433	+	
1434	—	
1435	rac	
1436	+	
1437	—	
1438	rac	
1439	+	
1440	—	

N.º	Racémico	o R3
-----	----------	------













495

63










	enantiómero	
1441	rac	
1442	+	
1443	—	
1444	rac	
1445	+	
1446	—	
1447	rac	
1448	+	
1449	—	
1450	rac	
1451	+	
1452	—	
1453	rac	
1454	+	
1455	—	
1456	rac	
1457	+	
1458	—	
1459	rac	
1460	+	
1461	—	
1462	rac	
1463	+	
1464	—	
1465	rac	
1466	+	
1467	—	
1468	rac	
1469	+	
1470	—	


496











64

1471	rac	
1472	+	
1473	—	
1474	rac	
1475	+	
1476	—	
1477	rac	
1478	+	
1479	—	
1480	rac	
1481	+	
1482	—	
1483	rac	
1484	+	
1485	—	
1486	rac	
1487	+	
1488	—	
1489	rac	
1490	+	
1491	—	
1492	rac	
1493	+	
1494	—	
1495	rac	
1496	+	
1497	—	
1498	rac	
1499	+	
1500	—	

497
65

N.º	Racémico enantiómero	o R3
1501	rac	
1502	+	
1503	—	
1504	rac	
1505	+	
1506	—	
1507	rac	
1508	+	
1509	—	
1510	rac	
1511	+	
1512	—	
1513	rac	
1514	+	
1515	—	
1516	rac	
1517	+	
1518	—	
1519	rac	
1520	+	
1521	—	
1522	rac	
1523	+	
1524	—	
1525	rac	
1526	+	
1527	—	











1528	rac	
1529	+	
1530	—	
1531	rac	
1532	+	
1533	—	
1534	rac	
1535	+	
1536	—	
1537	rac	
1538	+	
1539	—	
1540	rac	
1541	+	
1542	—	
1543	rac	
1544	+	
1545	—	
1546	rac	
1547	+	
1548	—	
1549	rac	
1550	+	
1551	—	
1552	rac	
1553	+	
1554	—	
1555	rac	
1556	+	
1557	—	
1558	rac	

499











67

1559	+	
1560	-	

N.º	Racémico enantiómero	o R3
1561	rac	
1562	+	
1563	-	
1564	rac	
1565	+	
1566	-	
1567	rac	
1568	+	
1569	-	
1570	rac	
1571	+	
1572	-	
1573	rac	
1574	+	
1575	-	
1576	rac	
1577	+	
1578	-	
1579	rac	
1580	+	
1581	-	
1582	rac	
1583	+	
1584	-	
1585	rac	




500
63

1586	+	
1587	—	
1588	rac	
1589	+	
1590	—	
1591	rac	
1592	+	
1593	—	
1594	rac	
1595	+	
1596	—	
1597	rac	
1598	+	
1599	—	
1600	rac	
1601	+	
1602	—	
1603	rac	
1604	+	
1605	—	
1606	rac	
1607	+	
1608	—	
1609	rac	
1610	+	
1611	—	
1612	rac	
1613	+	
1614	—	
1615	rac	
1616	+	

501

69

1617	—	
1618	rac	
1619	+	
1620	—	

14. Composición farmacéutica que contiene al menos un compuesto de la fórmula general I de acuerdo con una de las reivindicaciones 1 a 13 y eventualmente al menos otro principio activo junto con excipientes y/o coadyuvantes aceptables para uso farmacéutico.

15. Composición farmacéutica de acuerdo con la reivindicación 14 en la cual el ingrediente activo adicional es SERM (un modulador selectivo de receptor de estrógeno).

16. Composición farmacéutica de acuerdo con la reivindicación 14 en la cual el ingrediente activo puede ser

tamoxifeno, 5-(4-{5-[(RS)-(4,4,5,5,5-pentafluoropentil)sulfinil]pentiloxi}fenil)-6-fenil-8,9-dihidro-7H-benzociclohepten-2-ol (documento WO 00/03979), ICI 182 780 (7alfa-[9-(4,4,5,5-pentafluoropentilsulfinil)nonil]estra-1,3,5(10)-trien-3,17-beta-diol), 11beta-fluoro-7alfa-[5-(metil{3-[(4,4,5,5,5-pentafluoropentil)sulfanil]propil}amino)-pentil]estra-1,3,5(10)-trien-3,17beta-diol (documento WO 98/07740), 11beta-fluoro-7alfa-{5-[metil(7,7,8,8,9,9,10,10,10-nonafluorodecil)amino]pentil}estra-1,3,5(10)-trien-3,17beta-diol (documento WO 99/33855), 11beta-fluoro-17alfa-metil-7alfa-{5-[metil(8,8,9,9,9-pentafluorononil)amino]pentil}estra-1,3,5(10)-trien-3,17beta-diol (documento WO 03/045972), clomifeno, raloxifeno, así como otros compuestos de eficacia antiestrogénica, e inhibidores de la aromatasas tales como, p. ej., fadrozol, formestano, letrozol, anastrozol o atamestano.

17. Uso de compuestos de acuerdo con una de las reivindicaciones 1 a 13 para la preparación de un medicamento.

18. Uso de compuestos de acuerdo con una de las reivindicaciones 1 a 13 para la preparación de un medicamento para la prevención de enfermedades ginecológicas tales como endometriosis, leiomiomas de útero, hemorragias disfuncionales y dismenorrea.

19. Uso de compuestos de acuerdo con una de las reivindicaciones 1 a 13 para la preparación de un medicamento para la terapia y la prevención de tumores dependientes de hormonas.

20. Uso de compuestos de acuerdo con una de las reivindicaciones 1 a 13 para la preparación de un medicamento para la terapia y la prevención de carcinomas de mama.

21. Uso de compuestos de acuerdo con una de las reivindicaciones 1 a 13 para la preparación de un medicamento para la terapia y la prevención de carcinoma de endometrio.

22. Uso de compuestos de acuerdo con una de las reivindicaciones 1 a 13 para la preparación de un medicamento para la terapia y la prevención de carcinomas de ovario.

23. Uso de compuestos de acuerdo con una de las reivindicaciones 1 a 13 para la preparación de un medicamento para la terapia y la prevención de carcinomas de próstata.

24. Uso de compuestos de acuerdo con una de las reivindicaciones 1 a 13 para la preparación de un medicamento para la terapia de reemplazo hormonal femenina.

25. Uso de compuestos de acuerdo con una de las reivindicaciones 1 a 13 para el control de la fertilidad femenina.

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

503
X

Applicant's or agent's file reference 53338AWO		FOR FURTHER ACTION		See Form PCT/PEA/416
International application No. PCT/EP2006/006532		International filing date (day/month/year) 22.06.2006	Priority date (day/month/year) 24.06.2005	
International Patent Classification (IPC) or national classification and IPC INV. C07D307/83				
Applicant SCHERING AKTIENGESELLSCHAFT				
1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36. 2. This REPORT consists of a total of <u>5</u> sheets, including this cover sheet. 3. This report is also accompanied by ANNEXES, comprising: a. ☒ sent to the applicant and to the International Bureau a total of <u>79</u> sheets, as follows: ☒ sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions). ☐ sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box. b. ☐ (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or tables related thereto, in electronic form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).				
4. This report contains indications relating to the following items: ☒ Box No. I Basis of the report ☐ Box No. II Priority ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability ☐ Box No. IV Lack of unity of invention ☒ Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement ☐ Box No. VI Certain documents cited ☐ Box No. VII Certain defects in the international application ☐ Box No. VIII Certain observations on the international application				
Date of submission of the demand 2006-10-04		Date of completion of this report 09.10.2007		
Name and mailing address of the international preliminary examining authority:  European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016		Authorized officer Fritz, Martin Telephone No. +31 70 340-3024		



**INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY**

International application No.
PCT/EP2006/006532

504
A

Box No. I Basis of the report

1. With regard to the **language**, this report is based on
- ☒ the international application in the language in which it was filed
 - ☐ a translation of the international application into , which is the language of a translation furnished for the purposes of:
 - ☐ international search (under Rules 12.3(a) and 23.1(b))
 - ☐ publication of the international application (under Rule 12.4(a))
 - ☐ international preliminary examination (under Rules 55.2(a) and/or 55.3(a))
2. With regard to the **elements*** of the international application, this report is based on *(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):*

Description, Pages

1-72 as originally filed

Claims, Numbers

1-25 received on 04.10.2006 with letter of 29.09.2006

- ☐ a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing
3. ☐ The amendments have resulted in the cancellation of:
- ☐ the description, pages
 - ☐ the claims, Nos.
 - ☐ the drawings, sheets/figs
 - ☐ the sequence listing (*specify*):
 - ☐ any table(s) related to sequence listing (*specify*):
4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).
- ☐ the description, pages
 - ☐ the claims, Nos.
 - ☐ the drawings, sheets/figs
 - ☐ the sequence listing (*specify*):
 - ☐ any table(s) related to sequence listing (*specify*):

* If item 4 applies, some or all of these sheets may be marked "superseded."

**INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY**

International application No.
PCT/EP2006/006532

505



Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	<u>1-25</u>
	No: Claims	
Inventive step (IS)	Yes: Claims	<u>13</u>
	No: Claims	<u>1-12, 14-25</u>
Industrial applicability (IA)	Yes: Claims	<u>1-25</u>
	No: Claims	

2. Citations and explanations (Rule 70.7):

see separate sheet

506
JA

Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

D1: WO 03/075915 A (SCHERING AG; SCHMEES, NORBERT; LEHMANN, MANFRED; FUHRMANN, ULRIKE; MUH) 18 September 2003 (2003-09-18)

The present application relates to compounds of the general formula I (claims 1-13), pharmaceutical compositions thereof (claims 14-16) and the use thereof for the preparation of a pharmaceutical agent (claims 17-25).

The compounds I can be distinguished from the most preferred compound according to D1 (cf. structural formula (1) on p. 10) in the definition of R^3 which is an alkynyl substituted by R^a or an alkenyl substituted by R^g , R^h (the analogous substituent in the compound (1) of D1 is a trifluoromethyl group).

The subject-matter of claims 1-25 according to the present case is therefore novel in the sense of Article 33(2) PCT.

Closest prior art is D1.

The problem underlying the present application was to provide further compounds that are nonsteroidal progesterone receptor modulators and as such usefull for the treatment of certain gynecological disorders.

This problem has been solved by those compounds (I) in which
A designates a cyclic moiety and
 R^3 designates an optionally substituted alkynyl,
as can be seen in the description.

To arrive, starting from compound (1) of D1 at a representative of the compounds (I) according to the present case, a skilled man had to replace the trifluoromethyl moiety located in α -position of the amide moiety in this known compound by an optionally substituted alkynyl or alkenyl group. According to the broadest definition of the compounds disclosed in D1 (which is claim 1 of this document), the carbon located in α -position of the amide moiety must be substituted by a trifluoromethyl or, alternatively, a methyl group.

**INTERNATIONAL PRELIMINARY
REPORT ON PATENTABILITY
(SEPARATE SHEET)**

International application No.

PCT/EP2006/006532

The skilled man being aware of D1 had thus no incentive to replace this substituent by a chemically different group such like a optionally substituted alkynyl / alkenyl.

The compounds (I) according to the present case are, by consequence, not obvious in view of the compounds disclosed in D1.

It is, due to the (apparently too broad) definitions of A and R³ (vide supra) not clear, whether all compounds claimed are a solution to the problem; an inventive step in the sense of Article 33(3) PCT is therefore only acknowledged for the subject-matter of claim 13.

Further objections:

Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the document D1 is not mentioned in the description, nor is this document identified therein.


As amended claims have been filed, the description should be brought into conformity thereto (Art. 6 PCT). This can be done in an eventual national phase.

508
76

AMENDED CLAIMS
received by the International Bureau on 04 October 2006 (04.10.2006)
+STATEMENT

Claims

1. Compounds of general formula I



in which

R^1 and R^2 , independently of one another, mean a hydrogen atom, a straight or nonstraight, branched or unbranched C_1 - C_5 -alkyl group, also together with the C atom of the chain forming a ring with a total of 3-7 members,

R^3 means a radical $C\equiv C-R^a$, whereby

R^a means a hydrogen or a C_1 - C_8 -alkyl, C_2 - C_8 -alkenyl, C_2 - C_8 -alkinyl, C_3 - C_{10} -cycloalkyl, or heterocycloalkyl that optionally is substituted in one or more places, in the same way or differently, with K, or an aryl or heteroaryl that optionally is substituted in one or more places, in the same way or differently, with L,

K is a cyano, halogen, hydroxy, nitro, $-C(O)R^b$, CO_2R^b , $-O-R^b$, $-S-R^b$, $SO_2NR^cR^d$, $-C(O)-NR^cR^d$, $-OC(O)-NR^cR^d$, or $-C=NOR^b-NR^cR^d$ or a C_3 - C_{10} -cycloalkyl that optionally is substituted in one or more places, in the same way or differently, with M, heterocycloalkyl, or aryl or heteroaryl that optionally is substituted in one or more places with L,

L means C_1 - C_8 -alkyl, C_2 - C_8 -alkenyl, C_2 - C_8 -alkinyl, C_1 - C_6 -

509
77

perfluoroalkyl, C₁-C₆-perfluoroalkoxy, C₁-C₆-alkoxy-C₁-C₆-alkoxy, (CH₂)_p-C₃-C₁₀-cycloalkyl, (CH₂)_p-heterocycloalkyl, (CH₂)_pCN, (CH₂)_pHal, (CH₂)_pNO₂, (CH₂)_p-C₆-C₁₂-aryl, (CH₂)_p-heteroaryl, -(CH₂)_pPO₃(R^b)₂,
 -(CH₂)_pNR^cR^d, -(CH₂)_pNR^cCOR^b,
 -(CH₂)_pNR^cCSR^b, -(CH₂)_pNR^cS(O)R^b,
 -(CH₂)_pNR^cS(O)₂R^b, -(CH₂)_pNR^cCONR^cR^d,
 -(CH₂)_pNR^cCOOR^b, -(CH₂)_pNR^cC(NH)NR^cR^d,
 -(CH₂)_pNR^cCSNR^cR^d, -(CH₂)_pNR^cS(O)NR^cR^d,
 -(CH₂)_pNR^cS(O)₂NR^cR^d, -(CH₂)_pCOR^b,
 -(CH₂)_pCSR^b, -(CH₂)_pS(O)R^b,
 -(CH₂)_pS(O)(NH)R^b, -(CH₂)_pS(O)₂R^b,
 -(CH₂)_pS(O)₂NR^cR^d, -(CH₂)_pSO₂OR^b,
 -(CH₂)_pCO₂R^b, -(CH₂)_pCONR^cR^d,
 -(CH₂)_pCSNR^cR^d, -(CH₂)_pOR^b, -(CH₂)_pSR^b,
 -(CH₂)_pCR^b(OH)-R^e, -(CH₂)_p-C=NOR^b,
 -O-(CH₂)_n-O-, -O-(CH₂)_n-CH₂-, -O-CH=CH-

or -(CH₂)_{n+2}-, whereby n = 1 or 2, and the terminal oxygen atoms and/or carbon atoms are linked to directly adjacent ring-carbon atoms,

M means C₁-C₆-alkyl or a group -COR^b, CO₂R^b, -O-R^b, or -NR^cR^d, whereby

R^b means a hydrogen or a C₁-C₆-alkyl, C₂-C₈-alkenyl, C₂-C₈-alkinyl, C₃-C₁₀-cycloalkyl, C₆-C₁₂-aryl or C₁-C₃-perfluoroalkyl and

R^c and R^d, independently of one another, mean a hydrogen,

510
73

C₁-C₆-alkyl, C₂-C₈-alkenyl, C₂-C₈-alkinyl, C₃-C₁₀-cycloalkyl, C₆-C₁₂-aryl, C(O)R^b or a hydroxy group, whereby if

R^c is a hydroxy group, R^d can be only one hydrogen, a C₁-C₆-alkyl, C₂-C₈-alkenyl, C₂-C₈-alkinyl, C₃-C₁₀-cycloalkyl or C₆-C₁₂-aryl and vice versa, and

R^e means a hydrogen, C₁-C₆-alkyl, C₂-C₈-alkenyl, C₂-C₈-alkinyl, C₃-C₁₀-cycloalkyl or C₆-C₁₂-aryl, and

p can be a number from 0-6,

or

R³ is a radical C = C-R^gR^h, whereby

R^g and R^h, independently of one another, are a hydrogen or a C₁-C₈-alkyl, C₂-C₈-alkenyl or C₂-C₈-alkinyl that optionally is substituted in one or more places, in the same way or differently, with X, in which

X is a cyano, halogen, hydroxy, nitro, -C(O)R^b, CO₂R^b, -O-R^b, -C(O)-NR^cR^d, -NR^cR^d with the meanings, already further mentioned above, for R^b, R^c and R^d, and

R^{4a} and R^{4b}, independently of one another, mean a hydrogen atom, a C₁-C₄-alkyl, a C₂-C₄-alkenyl or together with the ring-carbon atom forming a 3- to 6-membered ring,

A means a monocyclic or bicyclic, carbocyclic or heterocyclic aromatic ring, which optionally can be substituted in one or more places with C₁-C₈-alkyl, C₂-C₈-alkenyl, C₂-C₈-alkinyl, C₁-C₆-perfluoroalkyl, C₁-C₆-perfluoroalkoxy, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxy, (CH₂)_p-C₃-C₁₀-cycloalkyl, (CH₂)_p-heterocycloalkyl, (CH₂)_pCN, (CH₂)_pHal, (CH₂)_pNO₂, (CH₂)_p-C₆-C₁₂-aryl, (CH₂)_p-heteroaryl,

79

$-(CH_2)_pPO_3(R^b)_2$, $-(CH_2)_pNR^cR^d$, $-(CH_2)_pNR^cCOR^b$, $-(CH_2)_pNR^cCSR^b$,
 $-(CH_2)_pNR^cS(O)R^b$, $-(CH_2)_pNR^cS(O)_2R^b$, $-(CH_2)_pNR^cCONR^cR^d$,
 $-(CH_2)_pNR^cCOOR^b$, $-(CH_2)_pNR^cC(NH)NR^cR^d$, $-(CH_2)_pNR^cCSNR^cR^d$,
 $-(CH_2)_pNR^cS(O)NR^cR^d$, $-(CH_2)_pNR^cS(O)_2NR^cR^d$, $-(CH_2)_pCOR^b$,
 $-(CH_2)_pCSR^b$, $-(CH_2)_pS(O)R^b$, $-(CH_2)_pS(O)(NH)R^b$, $-(CH_2)_pS(O)_2R^b$,
 $-(CH_2)_pS(O)_2NR^cR^d$, $-(CH_2)_pSO_2OR^b$, $-(CH_2)_pCO_2R^b$, $-(CH_2)_pCONR^cR^d$,
 $-(CH_2)_pCSNR^cR^d$, $-(CH_2)_pOR^b$, $-(CH_2)_pSR^b$, $-(CH_2)_pCR^b(OH)R^d$,
 $-(CH_2)_pC=NOR^b$, $-O-(CH_2)_n-O-$, $-O-(CH_2)_n-CH_2-$, $-O-CH=CH-$ or
 $-(CH_2)_{n+2}-$, whereby $n = 1$ or 2 , and the terminal oxygen atoms and/or carbon
atoms are linked to directly adjacent ring-carbon atoms, or

A means a radical $-CO_2R^b$, $C(O)NR^cR^d$, COR^b ,

or

A means an alkenyl group $-CR^5=CR^6R^7$, whereby

R^5 , R^6 and R^7 are the same or different and, independently of one another, mean
hydrogen atoms, halogen atoms, aryl radicals or an unsubstituted or partially or
completely fluorinated C_1 - C_5 -alkyl group, or

A means an alkynyl group $-C\equiv CR^5$, with the meaning cited above for R^5 , and

B means a carbonyl group or a CH_2 group

as well as their pharmaceutically acceptable salts.

2. Compounds according to claim 1, in which R^1 and R^2 mean a hydrogen atom, a methyl group or an ethyl group.

3. Compounds according to claim 1, in which R^1 and R^2 together with the C atom of the chain form a ring with a total of 3 to 7 links.

4. Compounds according to claims 1 to 3, in which R^3 means alkenyl, alkynyl, arylalkynyl, heteroarylalkynyl, cycloalkylalkynyl, or heterocycloalkylalkynyl.

5. Compounds according to one of the preceding claims, in which R^3 means a vinyl, ethinyl, propinyl, butinyl, pentinyl, hexinyl, heptinyl, octinyl, hydroxypropinyl, hydroxybutinyl, 3-hydroxy-3-methylbutinyl, hydroxypentinyl, carboxypropinyl, t-butylcarboxypropinyl, phenylethinyl, (hydroxyphenyl)ethinyl, (methoxyphenyl)ethinyl, (dimethylaminophenyl)ethinyl, (methylphenyl)ethinyl, (cyanophenyl)ethinyl, (trifluoromethyl)ethinyl, (diphenyl)ethinyl, (nitrophenyl)ethinyl, (tert-butylphenyl)ethinyl, (acetylphenyl)ethinyl, (acetoxyphehyl)ethinyl, (carboxyphenyl)ethinyl or a benzylethinyl group.

6. Compounds according to one of the preceding claims, in which A is an aromatic ring.

7. Compounds according to one of the preceding claims, in which A is preferably a phenyl or naphthyl radical.

8. Compounds according to claim 7, in which A is an unsubstituted phenyl radical or optionally a phenyl radical that is substituted in one or more places.

9. Compounds according to claim 8, whereby the phenyl radical is substituted with one or two halogen atoms or a trifluoromethyl group.

10. Compounds according to claim 9, in which the halogen atoms are chlorine and/or fluorine.



11. Compounds according to claims 1-8, in which A is an $-O-(CH_2)_n-O-$ or $-O-(CH_2)_n-CH_2-$ substituted phenyl ring, whereby the respectively directly adjacent ring-carbon atoms are linked.


12. Compounds according to one of the preceding claims, in which R^{4a} and R^{4b} , independently of one another, in each case are a hydrogen atom.

13. Compounds according to claims 1 to 12, namely:







513

281

No.	Racemic or Enantiomer	R3
1	rac	
2	+	
3	-	
4	rac	
5	+	
6	-	
7	rac	
8	+	
9	-	
10	rac	
11	+	
12	-	
13	rac	
14	+	
15	-	
16	rac	
17	+	
18	-	
19	rac	
20	+	
21	-	
22	rac	
23	+	







Q2

24	-	
25	rac	
26	+	
27	-	
28	rac	
29	+	
30	-	
31	rac	
32	+	
33	-	
34	rac	
35	+	
36	-	
37	rac	
38	+	
39	-	
40	rac	
41	+	
42	-	
43	rac	
44	+	
45	-	
46	rac	
47	+	
48	-	

515


87


49	rac	
50	+	
51	-	
52	rac	
53	+	
54	-	
55	rac	
56	+	
57	-	
58	rac	
59	+	
60	-	









516





~~8A~~


No.	Racemic or Enantiomer	R3
61	rac	
62	+	
63	-	
64	rac	
65	+	
66	-	
67	rac	
68	+	
69	-	
70	rac	
71	+	
72	-	
73	rac	
74	+	
75	-	
76	rac	
77	+	
78	-	
79	rac	
80	+	
81	-	
82	rac	






83	+	
84	-	
85	rac	
86	+	
87	-	
88	rac	
89	+	
90	-	
91	rac	
92	+	
93	-	
94	rac	
95	+	
96	-	
97	rac	
98	+	
99	-	
100	rac	
101	+	
102	-	
103	rac	
104	+	
105	-	
106	rac	
107	+	



108	-	
109	rac	
110	+	
111	-	
112	rac	
113	+	
114	-	
115	rac	
116	+	
117	-	
118	rac	
119	+	
120	-	

No.	Racemic or Enantiomer	R3
121	rac	
122	+	
123	-	
124	rac	
125	+	
126	-	
127	rac	












519

OT


128	+	
129	-	
130	rac	
131	+	
132	-	
133	rac	
134	+	
135	-	
136	rac	
137	+	
138	-	
139	rac	
140	+	
141	-	
142	rac	
143	+	
144	-	
		
145	rac	
146	+	
147	-	
148	rac	
149	+	
150	-	

88


151	rac	
152	+	
153	-	
154	rac	
155	+	
156	-	
157	rac	
158	+	
159	-	
160	rac	
161	+	
162	-	
163	rac	
164	+	
165	-	
166	rac	
167	+	
168	-	
169	rac	
170	+	
171	-	
172	rac	
173	+	
174	-	
175	rac	

88








176	+
177	-
178	rac
179	+
180	-



No.	Racemic or Enantiomer	R3
181	rac	
182	+	
183	-	
184	rac	
185	+	
186	-	
187	rac	
188	+	
189	-	
190	rac	
191	+	
192	-	
193	rac	
194	+	
195	-	



~~92~~


196	rac	
197	+	
198	-	
199	rac	
200	+	
201	-	
202	rac	
203	+	
204	-	
205	rac	
206	+	
207	-	
208	rac	
209	+	
210	-	
211	rac	
212	+	
213	-	
214	rac	
215	+	
216	-	
217	rac	
218	+	
219	-	
220	rac	

523

8/11



221	+	
222	-	
223	rac	
224	+	
225	-	
226	rac	
227	+	
228	-	
229	rac	
230	+	
231	-	
232	rac	
233	+	
234	-	
235	rac	
236	+	
237	-	
238	rac	
239	+	
240	-	

No.	Racemic or Enantiomer	R3









524

OK



241	rac	
242	+	
243	-	
244	rac	
245	+	
246	-	
247	rac	
248	+	
249	-	
250	rac	
251	+	
252	-	
253	rac	
254	+	
255	-	
256	rac	
257	+	
258	-	
259	rac	
260	+	
261	-	
262	rac	
263	+	
264	-	
265	rac	

525


Q2

266	+	
267	-	
268	rac	
269	+	
270	-	
271	rac	
272	+	
273	-	
274	rac	
275	+	
276	-	
277	rac	
278	+	
279	-	
280	rac	
281	+	
282	-	
283	rac	
284	+	
285	-	
286	rac	
287	+	
288	-	
289	rac	
290	+	

526
GFA







291	-	
292	rac	
293	+	
294	-	
295	rac	
296	+	
297	-	
298	rac	
299	+	
300	-	

No.	Racemic or Enantiomer	R3
301	rac	
302	+	
303	-	
304	rac	
305	+	
306	-	
307	rac	
308	+	
309	-	









527

05

310	rac	
311	+	
312	-	
313	rac	
314	+	
315	-	
316	rac	
317	+	
318	-	
319	rac	
320	+	
321	-	
322	rac	
323	+	
324	-	
325	rac	
326	+	
327	-	
328	rac	
329	+	
330	-	
331	rac	
332	+	
333	-	
334	rac	


528


Q10


335	+	
336	-	
337	rac	
338	+	
339	-	
340	rac	
341	+	
342	-	
343	rac	
344	+	
345	-	
346	rac	
347	+	
348	-	
349	rac	
350	+	
351	-	
352	rac	
353	+	
354	-	
355	rac	
356	+	
357	-	

529

AT








358	rac	
359	+	
360	-	

No.	Racemic or Enantiomer	R3
361	rac	
362	+	
363	-	
364	rac	
365	+	
366	-	
367	rac	
368	+	
369	-	
370	rac	
371	+	
372	-	
373	rac	
374	+	
375	-	
376	rac	
377	+	









530


98


378	-	
		
379	rac	
380	+	
381	-	
382	rac	
383	+	
384	-	
385	rac	
386	+	
387	-	
388	rac	
389	+	
390	-	
391	rac	
392	+	
393	-	
394	rac	
395	+	
396	-	
397	rac	
398	+	
399	-	
400	rac	

591

99





401	+	
402	-	
403	rac	
404	+	
405	-	
406	rac	
407	+	
408	-	
409	rac	
410	+	
411	-	
412	rac	
413	+	
414	-	
415	rac	
416	+	
417	-	
418	rac	
419	+	
420	-	

No.	Racemic or Enantiomer	R3
421	rac	











599

100

422	+	
423	-	
424	rac	
425	+	
426	-	
427	rac	
428	+	
429	-	
430	rac	
431	+	
432	-	
433	rac	
434	+	
435	-	
436	rac	
437	+	
438	-	
439	rac	
440	+	
441	-	
442	rac	
443	+	
444	-	
445	rac	
446	+	




533

101


447	-	
448	rac	
449	+	
450	-	
451	rac	
452	+	
453	-	
454	rac	
455	+	
456	-	
457	rac	
458	+	
459	-	
460	rac	
461	+	
462	-	
463	rac	
464	+	
465	-	
466	rac	
467	+	
468	-	
469	rac	
470	+	
471	-	

534

102






472	rac	
473	+	
474	-	
475	rac	
476	+	
477	-	
478	rac	
479	+	
480	-	

No.	Racemic or Enantiomer	R3
481	rac	
482	+	
483	-	
484	rac	
485	+	
486	-	
487	rac	
488	+	
489	-	











535

103

490	rac	
491	+	
492	-	
493	rac	
494	+	
495	-	
496	rac	
497	+	
498	-	
499	rac	
500	+	
501	-	
502	rac	
503	+	
504	-	
505	rac	
506	+	
507	-	
508	rac	
509	+	
510	-	
511	rac	
512	+	
513	-	
214	rac	

536

109


515	+	
516	-	
517	rac	
518	+	
519	-	
520	rac	
521	+	
522	-	
523	rac	
524	+	
525	-	
526	rac	
227	+	
528	-	
529	rac	
530	+	
531	-	
532	rac	
533	+	
534	-	
535	rac	
536	+	
537	-	
538	rac	
539	+	

537

105








540	-	
-----	---	--

No.	Racemic or Enantiomer	R3
541	rac	
542	+	
543	-	
544	rac	
545	+	
546	-	
547	rac	
548	+	
549	-	
550	rac	
551	+	
552	-	
553	rac	
554	+	
555	-	
556	rac	
557	+	
558	-	
559	rac	






538


108


560	+	
561	-	
562	rac	
563	+	
564	-	
565	rac	
566	+	
567	-	
568	rac	
569	+	
570	-	
571	rac	
572	+	
573	-	
574	rac	
575	+	
576	-	
577	rac	
578	+	
579	-	
580	rac	
581	+	
582	-	
583	rac	
584	+	

539

10X




585	-	
586	rac	
587	+	
588	-	
589	rac	
590	+	
591	-	
592	rac	
593	+	
594	-	
595	rac	
596	+	
597	-	
598	rac	
599	+	
600	-	

No.	Racemic or Enantiomer	R3
601	rac	
602	+	
603	-	
604	rac	












5401

108

605	+	
606	-	
607	rac	
608	+	
609	-	
610	rac	
611	+	
612	-	
613	rac	
614	+	
615	-	
616	rac	
617	+	
618	-	
619	rac	
620	+	
621	-	
622	rac	
623	+	
624	-	
625	rac	
626	+	
627	-	



541

109


628	rac	
629	+	
630	-	
631	rac	
632	+	
633	-	
634	rac	
635	+	
636	-	
637	rac	
638	+	
639	-	
640	rac	
641	+	
642	-	
643	rac	
644	+	
645	-	
646	rac	
647	+	
648	-	
649	rac	
650	+	
651	-	
652	rac	

542

110








653	+	
654	-	
655	rac	
656	+	
657	-	
658	rac	
659	+	
660	-	

No.	Racemic or Enantiomer	R3
661	rac	
662	+	
663	-	
664	rac	
665	+	
666	-	
667	rac	
668	+	
669	-	
670	rac	
671	+	
672	-	










543

171

673	rac	
674	+	
675	-	
676	rac	
677	+	
678	-	
679	rac	
680	+	
681	-	
682	rac	
683	+	
684	-	
685	rac	
686	+	
687	-	
688	rac	
689	+	
690	-	
691	rac	
692	+	
693	-	
694	rac	
695	+	
696	-	
697	rac	

544


1/2

698	+	
699	-	
700	rac	
701	+	
702	-	
703	rac	
704	+	
705	-	
706	rac	
707	+	
708	-	
709	rac	
710	+	
711	-	
712	rac	
713	+	
714	-	
715	rac	
716	+	
717	-	
718	rac	
719	+	
720	-	








549

113

No.	Racemic or Enantiomer	R3
721	rac	
722	+	
723	-	
724	rac	
725	+	
726	-	
727	rac	
728	+	
729	-	
730	rac	
731	+	
732	-	
733	rac	
734	+	
735	-	
736	rac	
737	+	
738	-	
739	rac	
740	+	
741	-	








546
114


742	rac	
743	+	
744	-	
745	rac	
746	+	
747	-	
748	rac	
749	+	
750	-	
751	rac	
752	+	
753	-	
754	rac	
755	+	
756	-	
757	rac	
758	+	
759	-	
760	rac	
761	+	
762	-	
763	rac	
764	+	

347





115

765	-	
766	rac	
767	+	
768	-	
769	rac	
770	+	
771	-	
772	rac	
773	+	
774	-	
775	rac	
776	+	
777	-	
778	rac	
779	+	
780	-	

No.	Racemic or Enantiomer	R3
781	rac	
782	+	
783	-	
784	rac	











116 548

785	+	
786	-	
787	rac	
788	+	
789	-	
790	rac	
791	+	
792	-	
793	rac	
794	+	
795	-	
796	rac	
797	+	
798	-	
799	rac	
800	+	
801	-	
802	rac	
803	+	
804	-	
805	rac	
806	+	
807	-	
808	rac	
809	+	

548

117


810	-	
811	rac	
812	+	
813	-	
814	rac	
815	+	
816	-	
817	rac	
818	+	
819	-	
820	rac	
821	+	
822	-	
823	rac	
824	+	
825	-	
826	rac	
827	+	
828	-	
829	rac	
830	+	
831	-	
832	rac	
833	+	
834	-	

550

118







835	rac	
836	+	
837	-	
838	rac	
839	+	
840	-	

No.	Racemic or Enantiomer	R3
841	rac	
842	+	
843	-	
844	rac	
845	+	
846	-	
847	rac	
848	+	
849	-	
850	rac	
851	+	
852	-	
853	rac	









551

119

854	+	
855	-	
856	rac	
857	+	
858	-	
859	rac	
860	+	
861	-	
862	rac	
863	+	
864	-	
865	rac	
866	+	
867	-	
868	rac	
869	+	
870	-	
871	rac	
872	+	
873	-	
874	rac	
875	+	
876	-	
877	rac	
878	+	



552


120

879	-	
880	rac	
881	+	
882	-	
883	rac	
884	+	
885	-	
886	rac	
887	+	
888	-	
889	rac	
890	+	
891	-	
892	rac	
893	+	
894	-	
895	rac	
896	+	
897	-	
898	rac	
899	+	
900	-	

543








121

No.	Racemic or Enantiomer	R3
901	rac	
902	+	
903	-	
904	rac	
905	+	
906	-	
907	rac	
908	+	
909	-	
910	rac	
911	+	
912	-	
913	rac	
914	+	
915	-	
916	rac	
917	+	
918	-	
919	rac	
920	+	
921	-	
922	rac	
923	+	







554

122


924	-	
925	rac	
926	+	
927	-	
928	rac	
929	+	
930	-	
931	rac	
932	+	
933	-	
934	rac	
935	+	
936	-	
937	rac	
938	+	
939	-	
940	rac	
941	+	
942	-	
943	rac	
944	+	
945	-	
946	rac	
947	+	
948	-	

555

123






949	rac	
950	+	
951	-	
952	rac	
953	+	
954	-	
955	rac	
956	+	
957	-	
958	rac	
959	+	
960	-	

No.	Racemic or Enantiomer	R3
961	rac	
962	+	
963	-	
964	rac	
965	+	
966	-	
967	rac	
968	+	











566


124


969	-	
970	rac	
971	+	
972	-	
973	rac	
974	+	
975	-	
976	rac	
977	+	
978	-	
979	rac	
980	+	
981	-	
982	rac	
983	+	
984	-	
985	rac	
986	+	
987	-	
988	rac	
989	+	
990	-	
991	rac	
992	+	
993	-	


125

994	rac	
995	+	
996	-	
997	rac	
998	+	
999	-	
1000	rac	
1001	+	
1002	-	
1003	rac	
1004	+	
1005	-	
1006	rac	
1007	+	
1008	-	
1009	rac	
1010	+	
1011	-	
1012	rac	
1013	+	
1014	-	
1015	rac	
1016	+	








726

1017	-	
1018	rac	
1019	+	
1020	-	

No.	Racemic or Enantiomer	R3
1021	rac	
1022	+	
1023	-	
1024	rac	
1025	+	
1026	-	
1027	rac	
1028	+	
1029	-	
1030	rac	
1031	+	
1032	-	
1033	rac	
1034	+	
1035	-	
1036	rac	










128


1037	+	
1038	-	
1039	rac	
1040	+	
1041	-	
1042	rac	
1043	+	
1044	-	
1045	rac	
1046	+	
1047	-	
1048	rac	
1049	+	
1050	-	
1051	rac	
1052	+	
1053	-	
1054	rac	
1055	+	
1056	-	
1057	rac	
1058	+	
1059	-	

560

128


1060	rac	
1061	+	
1062	-	
1063	rac	
1064	+	
1065	-	
1066	rac	
1067	+	
1068	-	
1069	rac	
1070	+	
1071	-	
1072	rac	
1073	+	
1074	-	
1075	rac	
1076	+	
1077	-	
1078	rac	
1079	+	
1080	-	

No.	Racemic or	R3
-----	------------	----









561

129

	Enantiomer	
1081	rac	
1082	+	
1083	-	
1084	rac	
1085	+	
1086	-	
1087	rac	
1088	+	
1089	-	
1090	rac	
1091	+	
1092	-	
1093	rac	
1094	+	
1095	-	
1096	rac	
1097	+	
1098	-	
1099	rac	
1100	+	
1101	-	
1102	rac	
1103	+	
1104	-	




562

130


1105	rac	
1106	+	
1107	-	
1108	rac	
1109	+	
1110	-	
1111	rac	
1112	+	
1113	-	
1114	rac	
1115	+	
1116	-	
1117	rac	
1118	+	
1119	-	
1120	rac	
1121	+	
1122	-	
1123	rac	
1124	+	
1125	-	
1126	rac	
1127	+	
1128	-	
1129	rac	

563

137









1130	+	
1131	-	
1132	rac	
1133	+	
1134	-	
1135	rac	
1136	+	
1137	-	
1138	rac	
1139	+	
1140	-	

No.	Racemic or Enantiomer	R3
1141	rac	
1142	+	
1143	-	
1144	rac	
1145	+	
1146	-	
1147	rac	
1148	+	
1149	-	
1150	rac	











564

732

1151	+	
1152	-	
1153	rac	
1154	+	
1155	-	
1156	rac	
1157	+	
1158	-	
1159	rac	
1160	+	
1161	-	
1162	rac	
1163	+	
1164	-	
1165	rac	
1166	+	
1167	-	
1168	rac	
1169	+	
1170	-	
1171	rac	
1172	+	
1173	-	
1174	rac	
1175	+	

565


133

1176	-	
1177	rac	
1178	+	
1179	-	
1180	rac	
1181	+	
1182	-	
1183	rac	
1184	+	
1185	-	
1186	rac	
1187	+	
1188	-	
1189	rac	
1190	+	
1191	-	
1192	rac	
1193	+	
1194	-	
1195	rac	
1196	+	
1197	-	
1198	rac	
1199	+	
1200	-	









566

139

No.	Racemic or Enantiomer	R3
1201	rac	
1202	+	
1203	-	
1204	rac	
1205	+	
1206	-	
1207	rac	
1208	+	
1209	-	
1210	rac	
1211	+	
1212	-	
1213	rac	
1214	+	
1215	-	
1216	rac	
1217	+	
1218	-	
1219	rac	
1220	+	
1221	-	








135

1222	rac	
1223	+	
1224	-	
1225	rac	
1226	+	
1227	-	
1228	rac	
1229	+	
1230	-	
1231	rac	
1232	+	
1233	-	
1234	rac	
1235	+	
1236	-	
1237	rac	
1238	+	
1239	-	
1240	rac	
1241	+	
1242	-	
1243	rac	
1244	+	


568


136

1245	-	
1246	rac	
1247	+	
1248	-	
1249	rac	
1250	+	
1251	-	
1252	rac	
1253	+	
1254	-	
1255	rac	
1256	+	
1257	-	
1258	rac	
1259	+	
1260	-	

569







137

No.	Racemic or Enantiomer	R3
1261	rac	
1262	+	
1263	-	
1264	rac	
1265	+	
1266	-	
1267	rac	
1268	+	
1269	-	
1270	rac	
1271	+	
1272	-	
1273	rac	
1274	+	
1275	-	
1276	rac	
1277	+	
1278	-	
1279	rac	
1280	+	
1281	-	







570

138


1282	rac	
1283	+	
1284	-	
1285	rac	
1286	+	
1287	-	
1288	rac	
1289	+	
1290	-	
1291	rac	
1292	+	
1293	-	
1294	rac	
1295	+	
1296	-	
1297	rac	
1298	+	
1299	-	
1300	rac	
1301	+	
1302	-	
1303	rac	
1304	+	
1305	-	

571

239




1306	rac	
1307	+	
1308	-	
1309	rac	
1310	+	
1311	-	
1312	rac	
1313	+	
1314	-	
1315	rac	
1316	+	
1317	-	
1318	rac	
1319	+	
1320	-	

No.	Racemic or Enantiomer	R3
1321	rac	
1322	+	
1323	-	
1324	rac	
1325	+	










572

100

1326	-	
1327	rac	
1328	+	
1329	-	
1330	rac	
1331	+	
1332	-	
1333	rac	
1334	+	
1335	-	
1336	rac	
1337	+	
1338	-	
1339	rac	
1340	+	
1341	-	
1342	rac	
1343	+	
1344	-	
1345	rac	
1346	+	
1347	-	
1348	rac	



573

141


1349	+	
1350	-	
1351	rac	
1352	+	
1353	-	
1354	rac	
1355	+	
1356	-	
1357	rac	
1358	+	
1359	-	
1360	rac	
1361	+	
1362	-	
1363	rac	
1364	+	
1365	-	
1366	rac	
1367	+	
1368	-	
1369	rac	
1370	+	
1371	-	
1372	rac	
1373	+	

574

142







1374	-	
1375	rac	
1376	+	
1377	-	
1378	rac	
1379	+	
1380	-	

No.	Racemic or Enantiomer	R3
1381	rac	
1382	+	
1383	-	
1384	rac	
1385	+	
1386	-	
1387	rac	
1388	+	
1389	-	
1390	rac	
1391	+	











575

143

1392	-	
1393	rac	
1394	+	
1395	-	
1396	rac	
1397	+	
1398	-	
1399	rac	
1400	+	
1401	-	
1402	rac	
1403	+	
1404	-	
1405	rac	
1406	+	
1407	-	
1408	rac	
1409	+	
1410	-	
1411	rac	
1412	+	
1413	-	
1414	rac	
1415	+	
1416	-	

576


124


1417	rac	
1418	+	
1419	-	
1420	rac	
1421	+	
1422	-	
1423	rac	
1424	+	
1425	-	
1426	rac	
1427	+	
1428	-	
1429	rac	
1430	+	
1431	-	
1432	rac	
1433	+	
1434	-	
1435	rac	
1436	+	
1437	-	
1438	rac	
1439	+	

577

145









1440	-	
------	---	--

No.	Racemic or Enantiomer	R3
1441	rac	
1442	+	
1443	-	
1444	rac	
1445	+	
1446	-	
1447	rac	
1448	+	
1449	-	
1450	rac	
1451	+	
1452	-	
1453	rac	
1454	+	
1455	-	
1456	rac	
1457	+	
1458	-	
1459	rac	



570

196


1460	+	
1461	-	
1462	rac	
1463	+	
1464	-	
1465	rac	
1466	+	
1467	-	
1468	rac	
1469	+	
1470	-	
1471	rac	
1472	+	
1473	-	
1474	rac	
1475	+	
1476	-	
1477	rac	
1478	+	
1479	-	
1480	rac	
1481	+	
1482	-	
1483	rac	

579

147





1484	+	
1485	-	
1486	rac	
1487	+	
1488	-	
1489	rac	
1490	+	
1491	-	
1492	rac	
1493	+	
1494	-	
1495	rac	
1496	+	
1497	-	
1498	rac	
1499	+	
1500	-	

No.	Racemic or Enantiomer	R3
1501	rac	
1502	+	
1503	-	









580

148

1504	rac	
1505	+	
1506	-	
1507	rac	
1508	+	
1509	-	
1510	rac	
1511	+	
1512	-	
1513	rac	
1514	+	
1515	-	
1516	rac	
1517	+	
1518	-	
1519	rac	
1520	+	
1521	-	
1522	rac	
1523	+	
1524	-	
1525	rac	
1526	+	




581

149


1527	-	
1528	rac	
1529	+	
1530	-	
1531	rac	
1532	+	
1533	-	
1534	rac	
1535	+	
1536	-	
1537	rac	
1538	+	
1539	-	
1540	rac	
1541	+	
1542	-	
1543	rac	
1544	+	
1545	-	
1546	rac	
1547	+	
1548	-	
1549	rac	
1550	+	
1551	-	

582

180









1552	rac	
1553	+	
1554	-	
1555	rac	
1556	+	
1557	-	
1558	rac	
1559	+	
1560	-	

No.	Racemic or Enantiomer	R3
1561	rac	
1562	+	
1563	-	
1564	rac	
1565	+	
1566	-	
1567	rac	
1568	+	
1569	-	
1570	rac	
1571	+	











583

151

1572	-	
1573	rac	
1574	+	
1575	-	
1576	rac	
1577	+	
1578	-	
1579	rac	
1580	+	
1581	-	
1582	rac	
1583	+	
1584	-	
1585	rac	
1586	+	
1587	-	
1588	rac	
1589	+	
1590	-	
1591	rac	
1592	+	
1593	-	
1594	rac	
1595	+	
1596	-	

584

152

1597	rac	
1598	+	
1599	-	
1600	rac	
1601	+	
1602	-	
1603	rac	
1604	+	
1605	-	
1606	rac	
1607	+	
1608	-	
1609	rac	
1610	+	
1611	-	
1612	rac	
1613	+	
1614	-	
1615	rac	
1616	+	
1617	-	
1618	rac	
1619	+	

585

25

1620	-	
------	---	--

14. Pharmaceutical composition that contains at least one compound of general formula I according to one of claims 1 to 13 and optionally at least one additional active ingredient together with pharmaceutically compatible adjuvants and/or vehicles.
15. Pharmaceutical composition according to claim 14, wherein the additional active ingredient is a SERM (selective estrogen receptor modulator), an aromatase inhibitor, an antiestrogen, or a prostaglandin.
16. Pharmaceutical composition according to claim 14, whereby the active ingredients can be tamoxifen, 5-(4-{5-[(RS)-(4,4,5,5,5-pentafluoropentyl)sulfinyl]-pentyloxy}phenyl)-6-phenyl-8,9-dihydro-7H-benzocyclohepten-2-ol, ICI 182 780 (7alpha-[9-(4,4,5,5-pentafluoropentylsulfinyl)nonyl]estra-1,3,5(10)-triene-3,17-beta-diol), 11beta-fluoro-7alpha-[5-(methyl{3-[(4,4,5,5,5-pentafluoropentyl)sulfanyl]propyl}amino)pentyl]estra-1,3,5(10)-triene-3,17beta-diol, 11beta-fluoro-7alpha-{5-[methyl(7,7,8,8,9,9,10,10,10-nonafluorodecyl)amino]pentyl}estra-1,3,5(10)-triene-3,17beta-diol, 11beta-fluoro-17alpha-methyl-7alpha-{5-[methyl(8,8,9,9,9-pentafluorononyl)amino]pentyl}estra-1,3,5(10)-triene-3,17beta-diol, clomifene, raloxifene, fadrozole, formestane, letrozole, anastrozole or atamestane.
17. Compounds according to one of claims 1 to 13 for the manufacture of a medicament.
18. Use of compounds according to claim 1-13 for the manufacture of a medicament for therapy and prophylaxis of gynecological diseases such as endometriosis, leiomyomas of the uterus, dysfunctional bleeding and dysmenorrhea.
19. Use of compounds according to claim 1-13 for the production of a pharmaceutical agent for therapy and prophylaxis of hormone-dependent tumors.

586

15A

20. Use of compounds according to claim 1-13 for the production of a pharmaceutical agent for therapy and prophylaxis of breast cancer.
21. Use of compounds according to claim 1-13 for the production of a pharmaceutical agent for therapy and prophylaxis of endometrial carcinoma.
22. Use of compounds according to claim 1-13 for the production of a pharmaceutical agent for therapy and prophylaxis of ovarian cancer.
23. Use of compounds according to claim 1-13 for the production of a pharmaceutical agent for therapy and prophylaxis of prostate cancer.
24. Use of compounds according to claim 1-13 for the production of a pharmaceutical agent for female hormone replacement therapy.
25. Use of compounds according to claim 1-13 for female birth control.

Protocolo No. R 17/2008

He explicado la prohibición de intervención según § 3 párrafo 1 No. 7 Ley de Documentación. A mi pregunta, si existe alguna versión previa en sentido de la norma, se contesto de forma negativa.

Yo certifico las firmas rendidas ante mi persona:

De la señora Anja **Schmidt**,
Nacida el 4 de septiembre de 1970

del señor Dr. Norbert **Schmees**,
Nacido el 10 de septiembre de 1969

del señor Carsten **Möller**,
Nacido el 26 de octubre de 1972

del señor Ulrich **Bothe**,
Nacido el 21 de febrero de 1972

- todos conocidos en persona -

con domicilio de negocios en 13353 Berlín, Müllerstrasse 178.

Berlín, 10 de enero de 2008

Firma

Notario

Watzke

Adolf Watzke
Traductor oficial

Res. 2433 Min. Justicia

Calculo de gastos según §§ 141, 154 reglamento de costos


Valor comercial: 12.000,00 Euros

Tarifa de legalización §§ 32, 45 I	15,00 Euro
Tarifa de gestión § 58	15,00 Euro
Gastos papelería §§ 136, 152	2,00 Euro
Gastos correo §§ 137, 152	<u>1,45 Euro</u>
	33,45 Euro
19 % IVA	<u>6,36 Euro</u>
	39,81 Euro

Berlín, 10 de enero de 2008

Firma

Notario



Adolf Watzke

Traductor oficial

Res. 2433 Min. Justicia

589

151

Yo certifico las firmas rendidas ante mi persona:

De la señora Ulrike **F u h r m a n n**,
nacida el 12 de mayo de 1959

del señor Dr. Wolfgang **S c h w e d e**
nacido el 30 de julio de 1963

- ambos conocidos en persona -

con domicilio de negocios en 13353 Berlin, Müllerstrasse 178.

Berlín, 15 de enero de 2008

Firma

Notario

Calculo de gastos según §§ 141, 154 reglamento de costos

Valor comercial: 12.000,00 Euros

Tarifa de legalización §§ 32,45 1	15,00 Euro
Tarifa de gestión § 58	15,00 Euro
Gastos papelería §§ 136, 152	2,00 Euro
Gastos correo §§ 137, 152	<u>4,35 Euro</u>
	36,35 Euro
19 % IVA	<u>6,91 Euro</u>
	43,26 Euro

Berlín, 15 de enero de 2008

Firma

Notario



Adolf Watzke

Traductor oficial

Res. 2433 Min. Justicia

590

150

APOSTILLA

(Convención de la Haya del 5 de octubre de 1961)

1. País: República Federal de Alemania

Este documento público

2. está firmado por Dimitri R e m p e n

3. en su calidad de Notario en Berlín

4. el documento está proveído con el sello del Notario

confirmado

5. en Berlín

6. el 18.01.2008

7. por el presidente de la audiencia provincial en Berlín

8. bajo el no. 9101 a E-F – 336/08

9. Sello:

10. Firma

Por orden

Firma ilegible

H a r t m a n n

Juez presidente de la audiencia provincial



Adolf Watzke

Traductor oficial

Res. 2433 Min. Justicia

Yo, (Nosotros), abajo firmado(s)

I (We), the undersigned,

- 1) SCHWEDE, Wolfgang
- 2) MOELLER, Carsten
- 3) SCHMIDT, Anja
- 4) FUHRMANN, Ulrike
- 5) SCHMEES, Norbert
- 6) BOTHE, Ulrich

159

domiciliado(s) en

of

- 1) Magdeburger Str. 41a,
16548 Glienicke, Germany
- 2) Windscheidstr. 22,
10627 Berlin, Germany
- 3) Wielandstr. 11,
10529 Berlin, Germany
- 4) Charlottenburger Ufer 4,
10587 Berlin, Germany
- 5) Bondickstr. 61,
13469 Berlin, Germany
- 6) Bredowstr. 24,
10551 Berlin, Germany

declaro(amos) bajo juramento ser
único(s) y verdadero(s) inventor(es)
de la invención:

state(s) under oath to be sole and
true inventor(s) of the invention

**BENZOFURANONE DERIVATIVES AS
NONSTEROIDAL PROGESTERONE
RECEPTOR MODULATORS**

declaro(amos) así mismo que cedo(emos)
y transfiero(erimos), sin limitación,
a favor de la sociedad

state as well, that assign, without
reservations or limitations in
favour of

**Bayer Schering Pharma
Aktiengesellschaft**

constituída y existente de conformidad
con las leyes de

a corporation constituted and existing
in conformity with the laws of

Germany

domiciliada en

domiciled in

**Müllerstr. 178,
13353 Berlin, Germany**

todos los derechos inherentes a
dicha invención y que la citada
Compañía queda facultada para
solicitar en su nombre la patente
correspondiente en la República de
Colombia

all rights inherent to said invention
and that the above mentioned company
hereby is enabled to apply, in its
name, for the corresponding patent
in the Republic of Colombia.

Dado y firmado hoy / Given and signed this
en/in

10 January 2008

1) Wally Sinedo
3) Aya
5) Robert Sel

2) P. Hall
4) R. Fubay
6) Ula'u Boh

392

160

AUTENTICACION NOTARIAL (INDIVIDUO)

A los dias del mes de

20

ante mí, Notario Público de

compareció(eron) personalmente

a quien(es) doy fe de conocer y me
consta que es(son) la(s) persona(s)
firmante(s) del documento que precede,
y quien(es) tiene(n) capacidad legal
para otorgarlo.

NOTARIAL AUTHENTICATION (INDIVIDUAL)

On this day of

20

before me, a Notary Public of

personally appeared

to me known, an known to me to be the
person(s) who executed that foregoing
document, and who has(have) legal
capacity to execute it.

393

Ich habe das Mitwirkungsverbot nach § 3 Abs. 1 Nr. 7 BeurkG erläutert. Meine Frage, ob eine Vorbefassung im Sinne der Vorschrift vorliege, wurde verneint.

Die vor mir geleisteten Unterschriften

161

der Frau Anja **Schmidt**,
geboren am 4. September 1970,

des Herrn Dr. Norbert **Schmees**,
geboren am 10. September 1969,

des Herrn Carsten **Möller**,
geboren am 26. Oktober 1972,

des Herrn Ulrich **Bothe**,
geboren am 21. Februar 1972,


- alle von Person bekannt -

alle geschäftsansässig in 13353 Berlin, Müllerstraße 178,

beglaubige ich.

Berlin, 10. Januar 2008

Notar



Kostenberechnung gem. §§ 141, 154 KostO

Geschäftswert: 12.000,00 €

Beglaubigungsgebühr §§ 32, 45 I

Wegegebühr gem. § 58

Schreibauslagen §§ 136, 152

Postauslagen §§ 137, 152

19 % Mehrwertsteuer

15,00 €

15,00 €

2,00 €

1,45 €

33,45 €

6,36 €

39,81 €

Berlin, 10. Januar 2008

Notar

Ich habe das Mitwirkungsverbot nach § 3 Abs. 1 Nr. 7 BeurkG erläutert. Meine Frage, ob eine
Vorbefassung im Sinne der Vorschrift vorliege, wurde verneint.

Die vor mir geleisteten Unterschriften

der Frau Dr. Ulrike **F u h r m a n n**,
geboren am 12. Mai 1959,


des Herrn Dr. Wolfgang **S c h w e d e**,
geboren am 30. Juli 1962,

- beide von Person bekannt -

beide geschäftsansässig in 13353 Berlin, Müllerstraße 178,

beglaubige ich.

Berlin, 15. Januar 2008



Notar

Kostenberechnung gem. §§ 141, 154 KostO

Geschäftswert: 12.000,00 €

Beglaubigungsgebühr §§ 32, 45 I


Wegegebühr gem. § 58

Schreibauslagen §§ 136, 152

Postauslagen §§ 137, 152

19% Mehrwertsteuer

Berlin, 15. Januar 2008



Notar

15,00 €

15,00 €

2,00 €


4,35 €

36,35 €

6,91 €

43,26 €

594
162



Apostille
(Convention de La Haye du 5 octobre 1961)

1. Land: Bundesrepublik Deutschland

Diese öffentliche Urkunde

2. ist unterschrieben von Dimitri R e m p e n

3. in seiner Eigenschaft als Notar in Berlin

4. sie ist versehen mit den Siegeln

des Notars

Bestätigt

5. in Berlin 6. am 18.01.2008


7. durch den Präsidenten des Landgerichts in Berlin

8. unter Nr. 9101a E-F 336/08

9. Siegel/
Stempel



10. Unterschrift
Im Auftrage



H a r t m a n n

(Vorsitzender Richter am Landgericht)

REPUBLICA DE COLOMBIA
SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

Folio 596

2020
Bogotá D.C.,

Doctor(a)
RAISBECK J. IAN
Apoderado(a) y/o Representante de
BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

REFERENCIA	Radicación No.	7 135475
	Solicitud internacional	PCT/EP2006/006532
	Fecha inicio fase nacional	24/01/2008
	Trámite	11
	Evento	379
	Actuación	416
	Oficio No.	7209
	Folios	1

Teniendo en cuenta que la solicitud de privilegio de patente que se tramita bajo el expediente indicado en la referencia, reúne los requisitos de forma establecidos en la Decisión 486 de la Comisión de la Comunidad Andina, el Tratado de Cooperación en Materia de Patentes (PCT), el Reglamento y la Circular Única de la Superintendencia de Industria y Comercio, se envía el extracto de la solicitud a la Oficina de Comunicaciones para efecto de su publicación en la Gaceta de Propiedad Industrial.

Cumplase
Dado en Bogotá DC,

26 NOV. 2008

ALIX CARMENZA CESPEDES DE VERGEL
Jefe de la división de Nuevas Creaciones

adpall

SI _____ NO _____ X _____